It's My Life
It's My Life It's My Life Hemophilia Village
Information for Consumers
Prescribing Information Indications/Safety Information Tell a Colleague Site Map
It's My Life

Home
HCP Home
About BeneFIX
About ReFacto
Summary
ReFacto Efficacy
Safety and Tolerability
Manufacturing Process
Innovative Recombinant Technology
ReFacto Convenience
Trial Prescription Program
ReFacto faq
ReFacto PI
Programs & Services
 
Wyeth

Convenience

  • ReFacto was the first recombinant factor VIII product to have the 2000 IU vial available21,48
    • One of the largest one-dose vials available16-20
    • Fewer vials per infusion and faster reconstitution times
  • Broad range of vial sizes (250 IU, 500 IU, 1000 IU, and 2000 IU) for flexible dosing16
  • Low Volume per vial of reconstituted product (4 mL)16
  • Room-temperature storage16*
  • Color-coded packaging for easy identification

*Not to exceed 77ºF (25ºC) for up to 3 months.

Rapid Reconstitution With the ReFacto R2 Kit

  • Prefilled diluent syringe
  • Needle-less reconstitution
  • Fewer components
  • Faster overall reconstitution process
  • Included with supply of ReFacto


† Compared with previous ReFacto reconstitution process.

Indication
ReFacto is indicated for the control and prevention of hemorrhagic episodes and for surgical prophylaxis and for short-term routine prophylaxis to reduce the frequency of spontaneous bleeding episodes in patients with hemophilia A. The effect of regular routine prophylaxis on long-term morbidity and mortality is unknown.

Important Safety Information
As with the intravenous administration of any protein product, adverse reactions may include headache, fever, chills, flushing, nausea, vomiting, tiredness, or symptoms of allergic reactions.
The remote possibility exists for hypersensitivity to non-human mammalian proteins. Known hypersensitivity to mouse or hamster proteins may be a contraindication to the use of ReFacto.
Allergic reactions such as hives, itching, difficulty breathing, rapid heart rate, light-headedness and anaphylaxis have been reported for all factor VIII products. Patients should discontinue use of the product and contact their health care provider immediately and/or seek emergency care if any of these symptoms occur.

Please see ReFacto Prescribing Information

The health information contained herein is provided for educational purposes only and is not meant to replace personal discussions between health care providers and patients. All decisions about patient care must be made with a health care provider who can assess the special needs of each individual patient.


   
Privacy Policy | Terms and Conditions
The information on this site is only intended for residents of the United States.
© 2007, Wyeth Pharmaceuticals Inc., Philadelphia, PA 19101
119533-01